(NASDAQ: GLTO) Galecto's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Galecto's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast GLTO's revenue for 2027 to be $754,221,005, with the lowest GLTO revenue forecast at $754,221,005, and the highest GLTO revenue forecast at $754,221,005. On average, 1 Wall Street analysts forecast GLTO's revenue for 2028 to be $957,078,204, with the lowest GLTO revenue forecast at $957,078,204, and the highest GLTO revenue forecast at $957,078,204.
In 2029, GLTO is forecast to generate $2,838,699,376 in revenue, with the lowest revenue forecast at $2,838,699,376 and the highest revenue forecast at $2,838,699,376.